Lucid Diagnostics Inc (NASDAQ: LUCD) established initial surge of 4.20% at $1.24, as the Stock market unbolted on Wednesday, before settling in for the price of $1.19 at the close. Taking a more long-term approach, LUCD posted a 52-week range of $0.80-$1.80.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -54.43%. Meanwhile, its Annual Earning per share during the time was -54.43%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 38.48%. This publicly-traded company’s shares outstanding now amounts to $130.92 million, simultaneously with a float of $92.31 million. The organization now has a market capitalization sitting at $162.56 million.
Lucid Diagnostics Inc (LUCD) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Lucid Diagnostics Inc industry. Lucid Diagnostics Inc’s current insider ownership accounts for 28.17%, in contrast to 27.75% institutional ownership. According to the most recent insider trade that took place on Aug 20 ’25, this organization’s Director bought 100,000 shares at the rate of 1.02, making the entire transaction reach 101,840 in total value, affecting insider ownership by 665,443. Preceding that transaction, on May 20 ’25, Company’s Director bought 187,098 for 1.29, making the whole transaction’s value amount to 242,292. This particular insider is now the holder of 187,098 in total.
Lucid Diagnostics Inc (LUCD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
Lucid Diagnostics Inc’s EPS increase for this current 12-month fiscal period is 38.48% and is forecasted to reach -0.30 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 31.40% through the next 5 years, which can be compared against the -54.43% growth it accomplished over the previous five years trading on the market.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
Let’s observe the current performance indicators for Lucid Diagnostics Inc (LUCD). It’s Quick Ratio in the last reported quarter now stands at 1.87. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 36.95.
In the same vein, LUCD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.90, a figure that is expected to reach -0.09 in the next quarter, and analysts are predicting that it will be -0.30 at the market close of one year from today.
